Personalised treatments to be trialed for lung cancer patients

Posted on 17 Apr 2014 by Tim Brown
Dot-like staining along the nuclear membrane is a characteristic feature of this immunostain in small cell lung carcinoma - photo courtesy of Yale Rosen.

Cancer Research UK is partnering with major pharmaceutical companies, AstraZeneca and Pfizer, to conduct a clinical trial to help develop personalised medical treatments for patients with advanced lung cancer.

The ‘National Lung Matrix’ trial – scheduled to open later this year at centres across the UK – will give researchers unprecedented access to libraries of drugs developed by AstraZeneca and Pfizer, allowing several to be tested at the same time, within one trial. Researchers will use the genetics of each lung tumour to identify…

This content is for subscribers only. Subscribe now for free to read the full article.